Seattle, WA -- (SBWIRE) -- 10/01/2019 -- Next Generation Sequencing (NGS) is used in various aspects of biological studies. This flexible and indispensable tool helps to generate genome-wide sequence data in a couple of days. The approach is highly parallelized and enables to sequence several molecules simultaneously. NSG helps to determine the sequenced data from amplified single DNA fragments, which helps to avoid the need for cloning of DNA fragments.

The use of NGS in the field of biological sciences is diverse and has allowed researchers to gather valuable information in public health studies and epidemiology, to sequence viruses and bacteria, and to help detect causes that may contribute to virulence. Next generation sequencing of RNA is preferred over microarray analysis in gene expression research as it enables researchers to see RNA expression sequence. RNA sequencing can, in turn, offer data on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

Get PDF Brochure of Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/158

The global next generation sequencing market was valued at US$ 5.6 billion in 2017 and is expected to witness a robust CAGR of 18.1% over the forecast period (2017–2025).

Increasing demand for early detection of cancer and infectious diseases is expected drive growth of the NGS market

Early detection of cancer and infectious diseases increases chances of successful treatment. NSG can aid in early detection of diseases. Increasing prevalence of cancer and other infectious diseases is one of the major factors boosting growth of the next generation sequencing market. For instance, according to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.

According to the statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Such scenario leads to high demand for early diagnosis of cancer and infectious diseases, which is expected to contribute to growth of the market over the forecast period.

Increasing demand for DNA testing

Advancements in whole genome and exome sequencing procedures, faster results, and cost effectives of the process as compared to genotyping based DNA microarray has increased the demand for DNA testing. In December, 2014, Oxford Nanopore Technologies introduced MinIon, the first commercial sequencer, using Nanopore technology. The sequencer identifies DNA by measuring the changes in the electrical conductivity generated by DNA strands passing through biological pore. This technology enabled the detection of outbreaks such as Zika virus. Furthermore, GenapSys, a U.S.-based developer of DNA sequencing technologies for applied genomic testing, introduced GENIUS sequencer, which can sequence DNA anywhere.

Key players in the next generation sequencing market include, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.

Obtain Complete Insights Into The Global Keyword Market Study: https://www.coherentmarketinsights.com/market-insight/next-generation-sequencing-market-158

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.